Journal · Rheumatology · Updated 21 November 2026
Rheumatology International
Read Rheumatology International articles on DeepDyve. No university library needed.
Rheumatology International has published research across rheumatology since 1981, covering inflammatory arthritis, lupus, systemic sclerosis and other autoimmune rheumatic diseases, along with their diagnosis, treatment and complications. Springer Nature publishes it. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.
Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.
Personal plans aren’t for business use. Reading for work? See Enterprise.
Rheumatology International at a glance
- Full title
- Rheumatology International
- Abbreviation (NLM)
- Rheumatol Int
- Publisher
- Springer Nature
- Print ISSN
- 0172-8172
- Online ISSN (eISSN)
- 1437-160X
- First published
- 1981
- Subjects
- Rheumatology
- Access model
- Hybrid (46% free to read in 2026)
Ways to access Rheumatology International
46% of the articles Rheumatology International published from January 1 to November 18, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.
- Open access articles. 46% of Rheumatology International articles published from January 1 to November 18, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
- The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
- Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
- NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
- A library. Your university, hospital or public library may subscribe to Rheumatology International. Check its journal list and whether it offers remote access.
- DeepDyve. Read Rheumatology International articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.
Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.
Impact factor and metrics
Rheumatology International’s 2025 Journal Impact Factor is 3.5, and its 5-year Impact Factor is 3.2.
3.5
Journal Impact Factor (2025)
3.2
5-year Impact Factor (2025)
5 days
Median time to first decision
1.4M
Downloads (2025)
Source: journal metrics on the Rheumatology International homepage (Springer Nature), checked November 21, 2026. Impact Factor from Clarivate Journal Citation Reports.
Recent Rheumatology International research worth reading
Published January to May 2026. Summaries describe what the authors report.
-
Diagnostic performance of Prof. Valmed, ChatGPT-5 Thinking, and OpenEvidence in rheumatology: A comparative evaluation
Testing three large language models on 60 vignettes of rare rheumatic diseases, the authors report that OpenEvidence gave the most identical top diagnoses (35.0%) and ChatGPT-5 Thinking the highest total score, with broadly comparable accuracy across all three.
Kremer et al. · Rheumatology International, published online January 10, 2026 · DOI 10.1007/s00296-025-06068-y
-
Suboptimal contraceptive counseling and use in women with autoimmune rheumatic diseases of childbearing age: findings from a cross-sectional survey of patients
In a cross-sectional survey of 156 premenopausal women with autoimmune rheumatic diseases in Italy, Gerardi and colleagues report that 37.8% used no contraception, 71.0% of those on teratogenic drugs used none, and only 13.5% had discussed contraception with a healthcare provider.
Gerardi et al. · Rheumatology International, published online February 5, 2026 · DOI 10.1007/s00296-026-06074-8
-
Muscle-dominant ANCA-associated vasculitis: a single-center cohort study
Reviewing 72 consecutive patients with microscopic polyangiitis or granulomatosis with polyangiitis at one center, Yahata and colleagues report that 8 (11%) had muscle-dominant disease, all MPO-ANCA positive with normal creatine kinase despite MRI-confirmed muscle inflammation, and with higher rheumatoid factor levels.
Yahata et al. · Rheumatology International, published online May 23, 2026 · DOI 10.1007/s00296-026-06151-y
-
Blood biomarkers of inflammation and brain-derived neurotrophic factor can not be used to assess the effectiveness of collagen mesotherapy in chronic cervical myofascial pain syndrome. A pilot single-blind randomized study
In a pilot single-blind randomized study of 23 patients with chronic cervical myofascial pain syndrome, Koszela and colleagues report that collagen and lignocaine mesotherapy both reduced pain and disability, while blood inflammatory biomarkers and BDNF did not correspond with the clinical improvement.
Koszela et al. · Rheumatology International, published online March 2, 2026 · DOI 10.1007/s00296-026-06094-4
-
Systemic sclerosis and cardiovascular disease: an integrative perspective on immune–vascular mechanisms and emerging risk stratification strategies
In a narrative review, Marmelo and colleagues argue that cardiovascular involvement in systemic sclerosis is frequent, predominantly subclinical and driven by immune-mediated vasculopathy and myocardial fibrosis, and call for validated, disease-specific cardiovascular risk stratification tools.
Marmelo et al. · Rheumatology International, published online May 25, 2026 · DOI 10.1007/s00296-026-06127-y
Related journals
Questions about Rheumatology International
How can I read Rheumatology International articles without a subscription?
46% of Rheumatology International articles published from January 1 to November 18, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Rheumatology International articles online for $59 a month or $499 a year after a free first month.
What is the abbreviation for Rheumatology International?
Rheumatology International’s NLM (PubMed) abbreviation is Rheumatol Int.
What is the ISSN of Rheumatology International?
The print ISSN is 0172-8172 and the online ISSN is 1437-160X.
What is the impact factor of Rheumatology International?
Rheumatology International’s Journal Impact Factor is 3.5 (2025), and its 5-year Impact Factor is 3.2, according to Springer Nature’s published metrics.
Is Rheumatology International open access?
Rheumatology International is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 18, 2026, 129 of 280 Rheumatology International articles (46%) carry a Creative Commons license, per Crossref.
Rheumatology International articles on DeepDyve are licensed from Springer Nature. Journal facts as of 21 November 2026.
Start reading Rheumatology International today
One month free, then less than $2 a day. Rheumatology International, plus millions of articles from thousands of journals.



